Clinical Trial Update: Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome [Phase 4]

View source ↗

Summary

Phase 4 study evaluating guanfacine extended-release for reducing aggression and self-injurious behavior in Prader-Willi syndrome has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• Guanfacine Extended Release (guanfacine)

Snippet

Sponsor: Maimonides Medical Center | Conditions: Prader-Willi Syndrome, Aggression | Phase 4 | Status: COMPLETED